Evidence map›Paper›PMID 40707424›Full record

ReviewJournal of gynecologic oncology2026

Current status of carboplatin desensitization therapy for gynecologic malignancies.

Hiroshi Nishio, Koji Matsumoto, Hiroaki Komatsu, Mitsunori Morita, Takayuki Nagasawa, Jiro Suzuki, Shin Nishio, Mitsuya Ishikawa, Toyomi Satoh

Abstract readReview
In one paragraph

Review in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hiroshi NishioDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. nishio.z3@keio.jp.ORCID 0000-0002-4938-416X
Koji MatsumotoDepartment of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.ORCID 0000-0003-1907-0247
Hiroaki KomatsuDepartment of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.ORCID 0000-0002-4507-6848
Mitsunori MoritaDepartment of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.ORCID 0000-0003-3083-4519
Takayuki NagasawaDepartment of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.ORCID 0000-0001-8279-4649
Jiro SuzukiDepartment of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.ORCID 0000-0002-0684-8665
Shin NishioDepartment of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.ORCID 0000-0003-2526-630X
Mitsuya IshikawaDepartment of Gynecology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0001-8855-2966
Toyomi SatohDepartment of Obstetrics and Gynecology, Tsukuba University School of Medicine, Tsukuba, Japan.ORCID 0000-0002-6929-5463

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platinum-based chemotherapies are widely used in the treatment of gynecologic malignancies and are standard treatment for initial treatment and recurrent diseases. Due to the widespread use of platinum-based regimens, the management of platinum hypersensitivity reactions (HSRs) is an important issue for physicians treating gynecologic malignancies. Patients receiving multiple lines of platinum therapy, with long intervals between platinum lines and history of allergic reaction, and status of germline

Indexed as

Antineoplastic AgentsCarboplatinDesensitization, ImmunologicDrug HypersensitivityGenital Neoplasms, FemaleFemaleHumansAntineoplastic AgentsCarboplatinCarboplatinDrug HypersensitivityHypersensitivity

Identifiers

PMID40707424
PMCPMC12867667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.